5 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp07097 | K2F6K2 | KKFFFFFFKK | Synthetic | Positive charge–driven membrane disruption apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 1146.23 ± 346.83 μg/mL |
| dbacp07098 | K3F6K3 | KKKFFFFFFKKK | Synthetic | Positive charge–driven membrane disruption apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 123.10 ± 35.19 μg/mL |
| dbacp07099 | K4F6K4 | KKKKFFFFFFKKKK | Synthetic | Positive charge–driven membrane disruption apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 62.64 ± 9.55 μg/mL |
| dbacp07100 | K4F6K4 | KKKKFFFFFFKKKK | Synthetic | Positive charge–driven membrane disruption apoptosis | AnnexinV-FITC/PI double staining assay | A-549 | Lung Cancer | apoptotic cells (early and late) increased from 9.59 ± 1.00% to 43.03 ± 2.13% |
| dbacp07101 | K4F8K4 | KKKKFFFFFFFFKKKK | Synthetic | Positive charge–driven membrane disruption apoptosis | CCK-8 assay | A-549 | Lung Cancer | IC50 = 571.87 ± 66.23 μg/mL |